Clavulanic Acid

CHEMBL777 Phase 4 Одобрено Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
199.2 g/mol
LogP
-1.2
Phase
4

A beta-lactam compound that acts as a suicide inhibitor of bacterial beta-lactamase enzymes by forming an irreversible covalent bond with the enzyme's active site. When combined with susceptible beta-lactam antibiotics such as amoxicillin, it dramatically expands antibacterial coverage to include many resistant organisms. It is not used as a standalone antibiotic due to its weak intrinsic antibacterial activity.

Молекулярная масса

199,1600 g/mol

LogP

-1,20

TPSA

87,10 Ų

Правило пяти Липинского

Соответствует

Терапевтические области

Механизм действия

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell …

2D Структура

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21

InChI

InChI=1S/C8H9NO5/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4/h1,6-7,10H,2-3H2,(H,12,13)/b4-1-/t6-,7-/m1/s1

Molecular Formula

C8H9NO5

HBD / HBA

2 / 5

Вращаемые Связи

2

Тяжёлые Атомы

14

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

A beta-lactam compound that acts as a suicide inhibitor of bacterial beta-lactamase enzymes by forming an irreversible covalent bond with the enzyme's active site. When combined with susceptible beta-lactam antibiotics such as amoxicillin, it dramatically expands antibacterial coverage to include many resistant organisms. It is not used as a standalone antibiotic due to its weak intrinsic antibacterial activity.

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Yes, Clavulanic Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL777. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5280980. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.